ORCHPHARMAOrchid Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Debt/Equity: 0.28
- • Promoter holding: 59.1%
- • RSI: 53
- • MACD: fresh bullish crossover
- • Price vs EMA21: above
- • 6-month return: +95.9%
- • Pullback to 21-EMA signal (setup quality 59%)
Bull case
- • Debt/Equity: 0.28
- • Promoter holding: 59.1%
- • RSI: 53
- • MACD: fresh bullish crossover
Bear case
- • Revenue growth: -1.5% YoY
- • Profit growth: -79.4% YoY
- • Supertrend: bearish
- • Trend strength (ADX): 15
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -1.5% YoY
- • Profit growth: -79.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹43.78). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.